

The Efficacy of Moxibustion and Acupuncture Therapy for Ankylosing Spondylitis: A Protocol for an Overview of Systematic Reviews and Meta-analyses

Jun Chen

Jiangxi University of Traditional Chinese Medicine

Jun Xiong (✉ xiongjun196071@163.com)

Affiliated Hospital of Jiangxi University of TCM <https://orcid.org/0000-0002-4196-3351>

Lunbin Lu

Jiangxi University of Traditional Chinese Medicine

Siyuan Zhu

Jiangxi University of Traditional Chinese Medicine

Zhiying Zhong

Jiangxi University of Traditional Chinese Medicine

Genhua Tang

Jiangxi University of Traditional Chinese Medicine

Xingchen Zhou

Affiliated Hospital of JiangXi University of TCM

Han Guo

Affiliated Hospital of JiangXi University of TCM

Protocol

Keywords: ankylosing spondylitis, AS, moxibustion, acupuncture, Du-moxibustion, GRADE ,overview, protocol

Posted Date: September 9th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-72275/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background:Ankylosing Spondylitis (AS) is a complex and progressive autoimmune inflammatory disease with a worldwide prevalence ranging up to 0.9%. Several systematic reviews and meta-analyses of traditional Chinese medicine alternative therapies, such as acupuncture or moxibustion, have demonstrated the effectiveness of moxibustion and acupuncture in the treatment of ankylosing spondylitis. However, there is no relevant literature to comprehensively evaluate the evidence. The purpose of this overview is to synthesize and evaluate the reliability of evidence generated in the systematic review (SR) and meta-analysis of moxibustion and acupuncture as a primary or complementary therapy for patients with ankylosing spondylitis.

Methods:PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, Chinese National Knowledge Infrastructure[CNKI], Chinese VIP Information, Wanfang Database, and Chinese Biomedical Literature Database[CBM] were searched for systematic reviews and Meta-analysis that review the efficacy of acupuncture or moxibustion as the primary treatment for patients with Ankylosing Spondylitis. The literature published before August 2020 will be selected. Additionally, the relevant SRs and Meta-analyses that unpublished or ongoing will be searched in PROSPERO and INPLASY. The methodological guidelines for overviews will be used to reviews and extract data by two reviewers, and their will do it independently. Methodology quality will be analyzed by the AMSTAR-2 and the risk of bias by POBIS. For the included studies, we will adopt the following results as primary evaluation indicators: effective rate, Visual Analogue Scale (VAS) and Bath AS Disease Activity Index (BASDAI). Reviewers will assess the certainty of evidence by Grading of Recommendations Assessment, Development and Evaluation(GRADE).

Results: The results will be published in a peer-reviewed journal.

Conclusion: This overview will provide comprehensive evidence of moxibustion and acupuncture for patients with Ankylosing Spondylitis.

Registration number: INPLASY202080035

1. Background

1.1. Description of the condition.

Ankylosing spondylitis (AS), a common inflammatory rheumatic disease that affects primarily the sacroiliac joints and the axial skeleton^[1, 2], is characterized by inflammatory erosive osteopenia and unusual bony overgrowth^[3]. The adverse effects of AS not only include physical pain, impaired function and reduced quality of life, but may also have an impact on employment prospects^[4].

A number of epidemiological studies on AS show that the incidence of AS has a great correlation with gender and age^[1, 5-7]. In different countries, male patients constituted a 2-6.1-fold higher number of

patients than female, and had a significantly higher mean age at diagnosis^[10]. An recent epidemiological survey has shown that the AS prevalence rates in China was 0.29% and continues to increase^[6]. The incidence of AS in the United States has been reported from 0.2 to 0.55 in related epidemiological studies^[3, 8, 9]. AS tends to occur in the second and third decade of life^[2], as a result, the quality of life of patients is reduced, and the employment prospects of patients will also have a very negative impact^[4]. In a series of economic evaluation studies on AS conducted in the United States, AS represents a substantial burden both on society and individuals with AS. In the total cost of AS, the indirect costs caused by AS account for the majority^[4, 11-14]. In addition to the financial burden, AS also brings other extra-articular disease burden, such as Acute anterior uveitis (AAU), Cardiac conduction system abnormalities, aortic regurgitation, neurological sequelae, and amyloidosis^[2, 15-17]. The etiology and pathogenesis of AS remain unclear, but the most convincing hypothesis is immune mediation mechanism, including several cytokines like tumor necrosis factor (TNF), genetic factors, interaction between T cell response and environmental factors.^[18, 19] Besides, some relevant genetic studies have confirmed that the incidence of AS has a strong correlation with HLA-B27 that is found in about 90% of patients with AS.^[20-23]

The basic principles of treat for patients with AS should be based on the presentation of the disease, severity of symptoms, and some other factors. The best treatment needs combine the non-pharmacological with pharmacological treatment methods. Non-pharmacological therapy consists of spa treatment^[24], physical therapy, acupuncture, as well as moxibustion. Pharmacological therapy is the main treatment for As, in current studies and guidelines, nonsteroidal anti-inflammatory drugs (NSAIDs) are considered as the first choice for patients with AS, which works through inhibiting prostaglandin synthase from relieving pain, stiffness and inflammation^[25]. However, NSAIDs, are known to have side effects, such as gastrointestinal adverse reactions and adverse effects on the cardiovascular system, which could restrict their use^[26, 27]. In addition to the side effects, some patients with AS may be insensitive to NSAIDs, in the event of this, disease-modifying anti-rheumatic drugs (DMARDs) are the second-line therapy recommended for patients with AS^[29]. Meanwhile, Tumour necrosis factor (TNF)- α inhibitors (anti-TNFs) also play a significant role that suppress the immune system and reduce the inflammation in the joints for the patients with low sensitivity to NSAIDs.^[26, 30]

Although the majority of patients who suffered from AS experienced different relief of the disease after the use of aforementioned drugs, but those are palliative measures and do not change disease course^[2]. At the same time, the financial burden of taking medication forces many patients to seek other effective and accessible treatments.

1.2. Description of the intervention.

Acupuncture and moxibustion, as traditional Chinese medicine therapies, are also widely accepted complementary and substitution therapies in the world. It has already been confirmed that can effectively

improve the symptoms of AS patients, and has been widely used in rheumatic immune system diseases^[31].

Acupuncture refers to the treatment of alleviating pain or other symptoms of a disease by inserting a needle into an acupuncture point under the technical guidance of an experienced doctor to produce electrophysiological changes. Acupuncture includes electro-acupuncture, fire-needle, acupoint injection, auricular needle, etc.

Several studies have reported that needle insertion at acupoints not only can improve the blood indices with an increased volume of blood flow but also effectively reduce the release of local inflammatory mediators, and reduce inflammation and pain^[32, 33].

The mechanism of moxibustion is based on modern theory of thermal effect.

Moxibustion is a characteristic therapy that applies heat to acupoints by burning moxa or herbal material at the acupoints to be stimulated and the heat would be transferred to the skin and recognized by the thermal sensory receptors as invasive stimulation^[34]. When the thermal sensory receptors are activated by the heat thermal stimuli, the sensory signals are transmitted to the central nervous system via nerve fibers, thus producing therapeutic effects^[35]. The mechanism of moxibustion has reported by some SRs and Meta-analysis published in Chinese that moxibustion can effectively regulate the immune imbalance and inflammatory reaction in patients with AS^[36, 37].

The use of moxibustion, as an alternative therapy, in the treatment of patients with AS, not only can avoid the side effects of oral drugs, but also can reduce the patient's physical and financial burden.

1.3. The reason to perform this overview.

Recently, plenty of studies have been performed to examine the effect of Acupuncture and moxibustion treatments on AS. Some SR and meta-analysis have shown that acupuncture and moxibustion can provide some positive impact for patients with AS mainly involve regulate the immune imbalance and inflammatory reaction to reduce joint pain and systemic symptoms. However, the evidence supporting its effectiveness and safety is still limited.

In this overview, the goal was to review existing or not published but completed SRs and meta-analyses and to gather the information of the evidence for a comprehensive synthesis of evidence, and evaluate the level of evidence with GREAD to provide reliable evidence for clinical workforce and helping AS patients seek more reasonable treatments.

2. Methods

2.1. Registration

This overview will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols (PRISMA-P)^[38]. It is registered in the INPLASY (registration number, INPLASY202080032;

<https://inplasy.com/inplasy-2020-8-0035/>).

2.2. Inclusion criteria for this overview

PICOS will be applied, including Population, Intervention, Comparison, Outcome, and Study.

2.2.1. Types of studies

All relevant SRs and Meta-analyses of randomized controlled trials (RCTs) in which acupuncture or moxibustion were utilized as the treatment for the AS. No restrictions on country but language will be limited on English and Chinese.

2.2.2. Participants

Study participants are the patients with all types of AS and will not be restricted to age, sex or nationality.

2.2.3. Intervention

AS treatments include acupuncture (it includes electro-acupuncture, fire needle, acupoint injection, transcutaneous electrical acupoint stimulation, etc.) and moxibustion (in includes Du-moxibustion/long snake moxibustion, Thermal moxibustion,etc.).We also included trials that comparing acupuncture or moxibustion combined with another active treatment with other active treatment alone.

2.2.4. Comparator

The selected SRs or Meta-analyses should testify that the interventions were compared with a control group composed of placebo, sham acupuncture/moxibustion, no treatment or other active therapies.

2.2.5. Outcomes

Primary outcomes

effective rate, VAS, and BASDAI.

Secondary outcomes

FFD, OWD, CRP, ESR and Side effects.

2.3. Search strategy

Two investigators will retrieve the relevant SRs and Meta-analyses in the following databases: PubMed, Embase, the Cochrane Library, CNKI, Chinese VIP information, Wanfang Database and CBM, from inception until August 2020. The language will be restricted to Chinese and English. A comprehensive search strategy will be conducted, MeSH items and free words will be searched synchronously. The following search terms will be used: Ankylosing spondylitis, Spondylitis, Ankylosing, Ankylosing

Spondylarthritis, acupuncture, moxibustion, Du-moxibustion, long snake moxibustion, systematic review, meta-analysis, etc. The preliminary search strategy for PubMed is presented in Table 1.

Table 1
Search Strategy (PubMed).

Order	strategy
#1	Search "Spondylitis, Ankylosing"[Mesh]
#2	Search (((((Ankylosing Spondylitis[Title/Abstract]) OR Ankylosing Spondylarthritis [Title/Abstract]) OR Spondyloarthritis Ankylopoietica [Title/Abstract]) OR Spondylarthritides, Ankylosing[Title/Abstract])
#3	#1 OR #2
#4	Search "Acupuncture"[Mesh] OR "Moxibustion"[Mesh]
#5	Search ((((((Acupuncture[Title/Abstract]) OR Acupuncture Therapy[Title/Abstract]) OR Moxibustion[Title/Abstract]) OR Du moxibustion[Title/Abstract]) OR Long snake moxibustion[Title/Abstract])
#6	#4 AND #5
#7	Search "Systematic Reviews as Topic " [Mesh] OR "Systematic Review" [Publication Type]
#8	Search ((((((Systematic Reviews[Title/Abstract]) OR Systematic Review[Title/Abstract]) OR SR[Title/Abstract]) OR SRs[Title/Abstract]) OR Review[Title/Abstract])
#9	Search "Meta-Analysis as Topic " [Mesh] OR "Meta-Analysis" [Publication Type]
#10	#7 OR #8 OR #9
#11	#3 AND #6 AND #10

2.4. Studies selection

After searching, the duplicated studies will be removed initially from the retrieved studies by Endnote(X9). And then, two independent reviewers (SYZ and LBL) will screen titles, abstracts, and keywords of all retrieved studies for candidates according to the inclusion and exclusion criteria, we will obtain the full text of all possibly relevant studies. Excluded studies will be recorded with explanations. If it is uncertain whether to adopt because of the lack of information, GHT will try to contact authors of the original reports to obtain the information of lost.

During the procedure, disagreements will be resolved by discussion or consensus with the third reviewer (JX). Study selection will be performed in accordance with the PRISMA flowchart (Fig. 1).

2.5. Data extraction

To ensure that necessary information would not be lost, each of the SRs and Meta-analyses will be submitted to data extraction by two independent reviewers (JC and LBL) the following data will be extracted:

- (1) Study characteristics: author, country, year of publication, study design and database;
- (2) Population characteristics : sex, age, baseline diseases and sample size;
- (3) Methodological characteristics: information sources, intervention(s), comparison(s), bias assessment, and funding,etc.;

If there are any differences, we will resolve them by mutual discussion or by consensus with the third reviewer (JX).

2.6. Data analysis

2.6.1. Assessment of risk of bias.

Two authors(SYZ and LBL) evaluated the quality and risk of bias of the included SR/Meta-analysis independently using the Risk of Bias in Systematic reviews (ROBIS) tool and PRISMA^[39]. A consensus is reached by two reviewers through discussion, and independent decisions are made by experts (JX) if necessary.

2.6.2. Assessment of methodological and reporting quality.

The tool AMSTAR-2^[40], will be referenced to asses the methodological quality of the SRs and Meta-analyses by two separate reviewers (ZYZ and GHT). If disagreements occur, it would be solved through discussion between two reviewers or consult the expert's (JX) decision.

2.6.3.Assessment of evidence quality (GRADE).

The quality of evidence will be evaluated using the GRADE approach^[41]. The evidence quality of all outcomes will be rated on four levels (high, medium, low, or very low). Two reviewers (XCZ and HG) will conduct the assessment process separately and describe in detail the reasons for downgraded or upgraded outcomes affecting the quality of evidence to guarantee the reliability and transparency of results.

2.6.4. Dealing with missing data.

If the specific information are not be reported, we will attempt to contact the original author for relevant information. If the required information is not available, it will be explained in the article. Then, the analysis will rely on existing data, and discuss the potential impact of missing information.

2.7. Data synthesis

The original studies, possibly, would be overlap in the studies that we included. For this situation, we will take corresponding measures to solve the overlapping before data synthesis. If the major RCT are overlapping more than two-thirds, the higher quality review will be selected, conversely, both reviews will be retained.

Considering that only carry out qualitative evaluation instead of quantitative analysis, it produces significant overlaps and biased results.

The random-effects model ($I^2 \geq 50\%$) or fixed-effects model ($I^2 < 50\%$) will be selected according to the heterogeneity levels of the included SRs and meta-analyses. If the I^2 value is higher than 70%, the heterogeneity will be explored through discussion with the review team.

2.8. Subgroup analysis and investigation of heterogeneity.

If large heterogeneity is observed after data synthesis of the included systematic reviews and meta-analyses, subgroup analysis or sensitivity analysis will be performed to find the source of heterogeneity, and subgroups will be conducted according to the different type of AS, intervention measures or types of outcomes.

2.9. Assessment of reporting biases.

The publication bias will be assessed through funnel plots and Egger's test if sufficient numbers of SRs and Meta-analyses are included. All eligible trials will be included, regardless of their methodological quality.

2.10. Ethics and dissemination.

This study is based on published systematic reviews and meta-analysis, and does not involve personal data. Therefore, the ethical approvals and patient consent are not necessary. The articles in this overview will be submitted to peer-reviewed journals for publication according to the PRISMA-P guideline.

3. Discussion

Ankylosing spondylitis (AS) is a chronic, debilitating condition that causes severe back pain. It mainly affects the sacroiliac joints and axial skeleton, leading to spinal stiffness. AS affects 0.9% of the world's population, and most of the patients are men under 30 years old. AS is characterized by insidious onset, long disease course and high disability rate, and has gradually become a serious public health problem. [42]

Despite some SRs and meta-analyses about acupuncture and moxibustion for AS, the efficacy and safety of acupuncture and moxibustion treatment for AS has not been reviewed. At present, there is no relevant literature to evaluate the methods and report quality of these studies. This overview will systematically use the AMSTAR-2 and GRADE to assess the quality of available evidence.

This overview, meanwhile, presented do have some limitations, mostly due to the quality of the original research. First, primary studies with partial overlap between included SRs and meta-analyses, and the synthetic result may be affected by duplicate clinical trials. Besides, some necessary information may be missing in the included studies, because of the retrieval of literature is limited to Chinese and English

databases. But this overview is still expected to provide a better methods for the treatment of AS and provide reliable evidence for clinical staff.

Abbreviations

AS=Ankylosing Spondylitis, AMSTAR-2 = Assessment of Multiple Systematic Reviews-2, GRADE = Grading of Recommendations, Assessment, Development, and Evaluation, SRs = systematic reviews, PRISMA-P = Systematic Reviews and Meta-analyses Protocols, ROBIS = Risk of Bias in Systematic reviews, VAS = visual analogue scale, BASDAI=Bath Ankylosing Spondylitis Disease Activity Index, CPR=C-reactive protein, ESR=erythrocyte sedimentation rate, FFD=finger-to-floor distance, OWD=occiput to wall distance, TNF=tumor necrosis factor, AAU=Acute anterior uveitis.

Declarations

Jun Chen orcid:

0000-0003-0928-572X

Ethical Approval and Consent to participate

This study will not contain any individual data and will not prejudice individual rights, so ethics approval is not required. The study will be subject to rigorous peer review and may be published in a peer-reviewed journal.

Consent for publication

Results will be disseminated on peer-reviewed publication and conference presentations.

Availability of data and materials

Not applicable.

Competing interests

The authors have no conflicts of interest to declare.

Funding

This work was supported by Project of Jiangxi University of Traditional Chinese Medicine 1050 youth talent project (Grant number:5141900101), National Natural Science Foundation (Grant number:81573835), Distinguished Young Talents Plan of Jiangxi Province (Grant No. 20171BCB23093), and Natural Science Youth Foundation Key Projects of Jiangxi Province (Grant No. 20192ACB21007).

Author contributions

All authors have read and approved the publication of the protocol.

Conceptualization: Jun Chen, Jun Xiong

Data curation: Jun Chen, Lunbin Lu, Siyuan Zhu, Genhua Tang, Zhiying Zhong, Xingchen Zhou, Han Guo.

Formal analysis: Jun Chen, Lunbin Lu.

Investigation: Jun Xiong, Jun Chen.

Methodology: Jun Chen, Siyuan Zhu, Lunbin Lu.

Software: Genhua Tang, Zhiying Zhong.

Supervision: Jun Xiong, Xingchen Zhou.

Writing – original draft: Jun Xiong, Jun Chen, Siyuan Zhu, Lunbin Lu.

Writing – review & editing: Jun Xiong, Xingchen Zhou, Lunbin Lu, Siyuan Zhu.

Acknowledgements

The authors would like to thank the following people who either provided feedback on the protocol or supported the development of the methods: Jun Chen¹, Jun Xiong², Lunbin Lu³, Genhua Tang⁴, Siyuan Zhu⁵, Zhiying Zhong⁶, Xingchen Zhou⁷, Han Guo⁸.

References

1. Braun J, Sieper J. Ankylosing spondylitis. *Lancet*. 2007;369:1379–90.
2. Gouveia EB, Elmann D, Morales MS. Ankylosing spondylitis and uveitis: overview. *Rev Bras Reumatol*. 2012;52(5):742–56.
3. Smith JA. Update on ankylosing spondylitis: current concepts in pathogenesis. *Curr Allergy Asthma Rep*. 2015;15(1):489. 10.1007/s11882-014-0489-6.. ;). **doi**.
4. Boonen A. The burden of ankylosing spondylitis. *J Rheumatol Suppl*. 2006;78:4–11., **van der Linden SM**.

5. Alamanos Y, Papadopoulos NG, Voulgari PV, Karakatsanis A, Siozos C, Drosos AA. **Epidemiology of ankylosing spondylitis in Northwest Greece, 1983–2002. Rheumatology (Oxford).** 2004;43(5):615–618.
6. Zhao J, Huang C, Huang H. **et al.** Prevalence of ankylosing spondylitis in a Chinese population: a systematic review and meta-analysis. *Rheumatol Int.* 2020;40(6):859–72.
7. Gran JT, Husby G, Hordvik M. **Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromsø, northern Norway. Ann Rheum Dis.**
8. Reveille JD, Weisman MH. The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States. *Am J Med Sci.* 2013;345:431–6.
9. Dillon CF, Hirsch R. The United States National Health and Nutrition Examination Survey and the epidemiology of ankylosing spondylitis. *Am J Med Sci.* 2011;341(4):281–3.
10. Alamanos Y, Papadopoulos NG, Voulgari PV, Karakatsanis A, Siozos C, Drosos AA. **Epidemiology of ankylosing spondylitis in Northwest Greece, 1983–2002. Rheumatology (Oxford).** 2004;43(5):615–618.
11. Merino M, Braçe O, González-Domínguez A, Hidalgo-Vega Á, Garrido-Cumbrera M, Gratacós J. **Social economic costs of ankylosing spondylitis in Spain [published online ahead of print, 2020 Jun 30]. Clin Exp Rheumatol.** 2020.
12. King D, Mitchell SA, Keyzor I, Kiri S. Systematic Review of Societal Cost of Illness Evidence in Patients With Ankylosing Spondylitis. *Value Health.* 2014;17(7):A378.
13. Palla I, Trieste L, Tani C. **et al.** A systematic literature review of the economic impact of ankylosing spondylitis. *Clin Exp Rheumatol.* 2012;30(4 Suppl 73):136–41.
14. Boonen A. Socioeconomic consequences of ankylosing spondylitis. *Clin Exp Rheumatol.* 2002;20(6 Suppl 28):23–6.
15. Forsblad-d'Elia H, Wallberg H, Klingberg E, Carlsten H, Bergfeldt L. Cardiac conduction system abnormalities in ankylosing spondylitis: a cross-sectional study. *BMC Musculoskelet Disord.* 2013;14:237. **Published 2013 Aug 12.**
16. Bergfeldt L. HLA-B27-associated cardiac disease. *Ann Intern Med.* 1997;127(8 Pt 1):621–9.
17. Rodríguez-Muguruza S, Martínez-Morillo M, Holgado S. **et al.** Amiloidosis secundaria a espondiloartritis: estudio de 15 casos [Amyloidosis complicating spondyloarthropathies: Study of 15 cases]. *Med Clin (Barc).* 2015;145(8):327–31.
18. Lata M, Hettinghouse AS, Liu CJ. Targeting tumor necrosis factor receptors in ankylosing spondylitis. *Ann N Y Acad Sci.* 2019;1442(1):5–16.
19. Zou J, Appel H, Rudwaleit M, Thiel A, Sieper J. Analysis of the CD8 + T cell response to the G1 domain of aggrecan in ankylosing spondylitis. *Ann Rheum Dis.* 2005;64(5):722–9.
20. Chen B, Li J, He C. **et al.** Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (Review). *Mol Med Rep.* 2017;15(4):1943–51.

21. Mear JP, Schreiber KL, Münz C. **et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol.**
22. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. *N Engl J Med.* 1973;288(14):704–6.
23. Taurog JD. The role of HLA-B27 in spondyloarthritis. *J Rheumatol.* 2010;37(12):2606–16.
24. **van Tubergen A, Landewe R. van der Heijde D, et al. Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2001; 45: 430–38.**
25. Sari I, Haroon N. Radiographic Progression in Ankylosing Spondylitis: From Prognostication to Disease Modification. *Curr Rheumatol Rep.* 2018;20(12):82. **Published 2018 Nov 8.**
26. Golder V, Schachna L. Ankylosing spondylitis: an update. *Aust Fam Physician.* 2013;42(11):780–4.
27. Ward MM, Kuzis S. Medication toxicity among patients with ankylosing spondylitis. *Arthritis Rheum.* 2002;47:234–41.
28. Zochling J. **van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis.** 2006;65(4):423–32.
29. **van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet.** 2018;392(10162):2378–87.
30. Corbett M, Soares M, Jhuti G. **et al. Tumour necrosis factor- α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess.**
31. Lv Z-T, Zhou X, Chen A-M. Akupunktur versus krankheitsmodifizierende Antirheumatika in der Behandlung der ankylosierenden Spondylitis—eine Metaanalyse. *Complementary Medicine Research.* 2015;22(6):395–402.
32. BiYan L. Effect of acupuncture and moxibustion combined with conventional drugs on patients with ankylosing spondylitis. *Contemporary Chinese Medicine.* 2019;26(2):21–4, **33.**
33. LaiMing K. **Effect analysis of the comprehensive treatment of ankylosing spondylitis with Acupuncture and moxibustion of Traditional Chinese medicine.GUANGMING ZHONGYI.** 2015,30(08):1704–1705.
34. Cheng XN, **editor.** Chinese Acupuncture and Moxibustion. **Beijing:** Foreign Languages; 1987.
35. Chiu JH. How does moxibustion possibly work? *Evid Based Complement Alternat Med.* 2013;2013:198584.
36. Zhu X, Guo R, Yu X. **et al.** clinical observation of long snake moxibustion in the treatment of ankylosing spondylitis. *Mod Dis EducTrad Chin Med.* 2019;17:97–9.
37. Lv M, Hu X, Geng L. **et al.** Clinical observation of long snake moxibustion in the treatment of ankylosing spondylitis. *Bright Trad Chin Med.* 2018;33:2086–8.

38. Larissa S, David M, Mike C. **et al.** Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*. 2015;349:7647–17647.
39. Higgins Julian P, Altman A, Sterne J, **et al.** **Assessing risk of bias in included studies.** *Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series*. 2011; John Wiley & Sons, Ltd.
40. Shea BJ, Reeves BC, Wells G. **et al.** AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ Clin Res*. 2017;358:j4008.
41. **GRADE Working.** GroupGrading quality of evidence and strength of recommendations. *BMJ*. 2004;328:1490.
42. Fang F, Jian P, Lixiao X. **et al.** Identification of potential transcriptomic markers in developing ankylosing spondylitis: a meta-analysis of gene expression profiles. *Biomed Res Int*. 2015;2015:1–6.

Figures




Figure 1

Flowchart of literature selection.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [PRISMAPchecklist.docx](#)